| Document |
Document Title |
|
WO/2018/205299A1 |
Disclosed are a 4,5-disubstituted-1-hydro-pyrrole(2,3-f)quinolone-2,7,9-tric
arboxylate compound, an analogue of same or a derivative of same, the structure thereof is as represented by formula I: where R1 and R4 respectively are indepen...
|
|
WO/2018/205038A1 |
Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of...
|
|
WO/2018/206239A1 |
A poly-lysine derivative obtained by a process comprising the steps of (a) heating an aqueous lysine solution to boiling (b) increasing temperature of the aqueous lysine solution to a reaction temperature in the range of about 105°C to ...
|
|
WO/2018/208700A1 |
The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targe...
|
|
WO/2018/209290A1 |
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carb
oxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carb
oxamide using selective crystallization with chir...
|
|
WO/2018/206758A1 |
A polymeric stabilizing agent selected from poly-lysine derivatives obtained by the process comprising the steps of: I. heating an aqueous lysine solution to boiling II. increasing temperature of the aqueous lysine solution to a reaction...
|
|
WO/2018/198523A1 |
The present invention provides a compound having excellent oil-gelling capability. More specifically, the present invention provides a compound represented by formula (1) , or a salt of the compound. [In the formula: R1 is a straight cha...
|
|
WO/2018/196677A1 |
The present invention relates to a fluoroallylamine derivative and the use thereof. In particular, the present invention relates to a compound as shown in formula I, a prodrug, an isomer, an isotopically labelled compound, a solvate or a...
|
|
WO/2018/196812A1 |
Disclosed are a boric acid and borate ester compound, and a preparation method and use therefor. Specifically disclosed are a borate ester compound of formula I, a crystal form, and pharmaceutically acceptable salts, hydrates or solvates...
|
|
WO/2018/200931A1 |
The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cel...
|
|
WO/2018/196860A1 |
The present invention relates to the field of chemical synthesis, and in particular to an ammonium carboxylate compound, a crystal form and an amorphous substance thereof, and a preparation method therefor. The present invention prepares...
|
|
WO/2018/200943A1 |
Compounds are provided having one of the the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein...
|
|
WO/2018/194157A1 |
The present invention addresses the problem of providing a compound which has high HTP, while having high temperature dependence of the HTP. The present invention also addresses the problem of providing a liquid crystal composition, a cu...
|
|
WO/2018/195439A2 |
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
|
|
WO/2018/191789A1 |
The invention relates to compounds of Formula (I) and methods for their preparation. Also described are pharmaceutical compositions comprising a compound of Formula (I) and their use in the treatment or prevention of conditions associate...
|
|
WO/2018/194908A1 |
A method for preparing photoactive perovskite materials. The method comprises the steps of: introducing a lead halide and a first solvent to a first vessel and contacting the lead halide with the first solvent to dissolve the lead halide...
|
|
WO/2018/191719A1 |
A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid),...
|
|
WO/2018/191657A1 |
Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, G1, G2 and n are as defined herein. Use of the compounds as a component of lip...
|
|
WO/2018/184196A1 |
Provided are a method for preparing 2-arylmalonamide and applications of the method. The method uses 2-(cyclohexylene) malononitrile as raw material that undergoes an aromatization-hydrolysis reaction under the effects of an oxidizer and...
|
|
WO/2018/177865A1 |
The present invention relates to the use of compounds having an anti- heparanase activity of formu la [R - L1- Ar1- L - Ar]2- X, wherein X is selected from the group consisting of SO2, C1 -C4 a lkylene, linear or branched, and wherein Ζ...
|
|
WO/2018/181986A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/183523A1 |
An enhanced pyrotechnic composition including an obscurant, a fuel, an oxidizer, and a nonivamide-cyclic anhydride adduct.
|
|
WO/2018/177488A1 |
Acrylamide photoinitiators are provided, in which a photoinitiator moiety and an acrylamide are incorporated into the photoinitiator structure.
|
|
WO/2018/177151A1 |
Compounds such as vidofludimus and its analogues useful in modulating the activity of nuclear receptor FXR. Also disclosed are the methods for treating FXR-mediated disease or process in a mammal, comprising administering to the mammal a...
|
|
WO/2018/176158A1 |
There are provided PVP-PLA block copolymers as defined in Formula (I): I wherein, x is an initiator alcohol having a boiling point greater than 145°C, n is, on average, from 20 and 40, and m is, on average, from 10 and 40, wherein the b...
|
|
WO/2018/178693A1 |
A quaternary ammonium salt of formula (I): wherein X is a linking group; Y is O, NH or NR1 wherein R1 is H or an optionally substituted hydrocarbyl group; Q+ is a moiety that includes a quaternary ammonium cation; A- is an anion; R2 is a...
|
|
WO/2018/175601A1 |
The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides platinum compounds that are chemically modified to have one or more moieties that include hydrophobic portions. In s...
|
|
WO/2018/172783A1 |
There is described a method of reducing polymer tar build-up in the production of methyl methacrylate and/or methacrylic acid by the acetone cyanohydrin process. In the method a stabiliser is contacted with the amide stage reaction mediu...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/167264A1 |
The present invention relates to a phenalene-1-one compound, a photosensitizer composition comprising said phenalene-1-one compound, an article comprising said phenalene-1-one compound and/or photosensitizer composition and the use thereof.
|
|
WO/2018/165614A1 |
Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.
|
|
WO/2018/157232A1 |
Compositions comprising modulators of N-terminus activation of the androgen receptor, such as EPI-002 and EPI-506, and a second therapeutic agent are provided. Use of such compositions for treatment of various indications, including pros...
|
|
WO/2018/159028A1 |
The present invention provides an industrially excellent production method by which N-benzyl-2-bromo-3-methoxypropionamide can be safely produced in high yield at lower cost. The production method of the present application comprises, in...
|
|
WO/2018/146285A1 |
The present invention relates to a method for the production of organo-iodinated compounds, as well as the production intermediates thereof. More specifically, the present invention relates to a method for the production of organo-iodina...
|
|
WO/2018/148721A1 |
The present invention includes methods and compositions that inhibit AKR1C3 enzymatic activity and consequently reduces androgen receptor (AR) transactivation, AR and prostate specific antigen (PSA) expression levels in, for example, pro...
|
|
WO/2018/143140A1 |
Through the fusicoccin compound according to the present invention represented by general formula (1A), PPI stabilization effect can be enhanced. [In the formula, Y represents a carbonyl group, a sulfonyl group, or a substituted or unsub...
|
|
WO/2018/141276A1 |
Disclosed are a novel crystal form of a brivaracetam intermediate compound (I) and preparation method thereof, and a novel crystal form of brivaracetam and preparation method thereof, specifically a crystal form A of a compound I and a c...
|
|
WO/2018/143916A1 |
The present disclosure is drawn to an acrylamide-containing photo active co-solvent, including a bis-tris propane co-solvent or a polypropylene oxide amine co-solvent modified with an acryloyl group to form the acrylamide-containing phot...
|
|
WO/2018/139607A1 |
[Problem] To provide a complex which contains a tin ion (Sn2+) or a bismuth ion (Bi3+) with a high purity and is suitable for the production of a lead-free perovskite compound. [Solution] A complex which is represented by general formula...
|
|
WO/2018/138441A1 |
The invention relates to novel dissymmetric RN,N-dialkylamides of formula (I) in which: R1 represents a linear C1 to C4 alkyl, R2 represents a linear C1 to C10 alkyl, and R3 represents a linear or branched C6 to C15 alkyl, provided that ...
|
|
WO/2018/138369A1 |
The present invention relates to new malodour-counteracting agents of formula (I) or stereoisomers thereof, particularly useful in blocking the olfactory perception of androstenone, Formula (I), wherein R1, R2, R3,R4, R5, R6, R7 and X ha...
|
|
WO/2018/132899A1 |
Described herein is a method for treating, preventing, reducing, or delaying onset of, osteosarcoma lung metastasis in a subject, comprising: administering a therapeutically or prophylactically effective amount of a PPARγ agonist, an an...
|
|
WO/2018/135574A1 |
A method for producing N-(α-hydroxyethyl)formamide which comprises reacting formamide with acetaldehyde in a solvent in the presence of a basic catalyst in a reaction vessel, precipitating the obtained N-(α-hydroxyethyl)formamide in th...
|
|
WO/2018/136014A1 |
There is provided a formulation comprising a mixture of an organogelator powder and at least one solvent having a relative polarity in the range of 0.3 to 0.6, wherein the organogelator powder comprises a compound of formula (I) as defin...
|
|
WO/2018/132876A1 |
The present invention relates to novel glycine transport inhibitor compounds and their use for treating pain.
|
|
WO/2018/131575A1 |
The present invention addresses the problem of providing a novel methylmenthol derivative usable as a cool-sensation imparter or sense-stimulating agent which has none of an undesirable irritating feeling, a peculiar odor, bitterness, an...
|
|
WO/2018/124088A1 |
Provided are novel pest control agents, in particular, a bactericide and a nematicide. An alkylphenyl-substituted amide compound represented by formula (I) [wherein: G1 stands for a structure represented by G1-2, G1-3, G1-4, etc.; X1 sta...
|
|
WO/2018/123936A1 |
The present invention addresses the problem of providing a compound having exceptional light fastness (in particular, a liquid crystal compound having exceptional light fastness), said compound being useable, inter alia, in an optically ...
|
|
WO/2018/118059A1 |
Disclosed is a novel method for extraction of Oxyresveratrol from Artocarpus hirsutus.
|
|
WO/2018/114484A1 |
Described is a process for the preparation of a N-[2-(2-pyridinyl)ethyl]carboxamide derivative of general formula (I) or a salt thereof.
|
